PT Suparma Tbk
IDX:SPMA.JK
312 (IDR) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) IDR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,658,520.983 | 3,138,054.095 | 2,794,452.672 | 2,151,494.982 | 2,514,161.429 | 2,389,268.903 | 2,093,137.904 | 1,932,435.078 | 1,621,516.334 | 1,550,810.296 | 1,395,838.227 |
| Cost of Revenue
| 2,192,080.776 | 2,419,295.659 | 2,205,296.923 | 1,761,980.361 | 2,142,805.061 | 2,020,058.39 | 1,782,127.62 | 1,625,251.469 | 1,373,535.293 | 1,295,583.079 | 1,163,283.182 |
| Gross Profit
| 466,440.207 | 718,758.435 | 589,155.749 | 389,514.621 | 371,356.368 | 369,210.514 | 311,010.285 | 307,183.61 | 247,981.041 | 255,227.216 | 232,555.045 |
| Gross Profit Ratio
| 0.175 | 0.229 | 0.211 | 0.181 | 0.148 | 0.155 | 0.149 | 0.159 | 0.153 | 0.165 | 0.167 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 35,633.021 | 28,075.963 | 29,490.953 | 18,864.721 | 70,681.975 | 67,975.305 | 55,150.545 | 50,788.008 | 46,431.705 | 40,040.647 | 37,731.182 |
| Selling & Marketing Expenses
| 94,421.214 | 84,742.729 | 76,064.555 | 66,482.86 | 99,925.481 | 87,509.441 | 81,671.966 | 79,365.886 | 81,128.075 | 73,514.641 | 57,237.652 |
| SG&A
| 211,376.935 | 112,818.692 | 105,555.508 | 154,417.08 | 176,588.963 | 158,857.278 | 137,851.972 | 134,872.994 | 130,500.464 | 113,555.288 | 94,968.834 |
| Other Expenses
| 6,066.245 | 4,477.369 | 5,359.295 | -2,559.653 | -5,880.331 | -1,876.186 | 0 | -15,940.993 | 0 | 0 | 0 |
| Operating Expenses
| 211,376.935 | 192,453.797 | 180,942.404 | 156,976.733 | 182,469.294 | 160,733.465 | 137,851.972 | 150,813.987 | 130,500.464 | 124,099.598 | 212,040.327 |
| Operating Income
| 255,063.272 | 464,484.813 | 413,022.16 | 232,537.888 | 188,887.074 | 208,477.049 | 173,158.313 | 156,369.622 | 117,480.577 | 141,671.929 | 137,586.211 |
| Operating Income Ratio
| 0.096 | 0.148 | 0.148 | 0.108 | 0.075 | 0.087 | 0.083 | 0.081 | 0.072 | 0.091 | 0.099 |
| Total Other Income Expenses Net
| -17,214.447 | -33,038.875 | -35,512.533 | -37,034.45 | -12,246.713 | -98,803.731 | -51,849.378 | -45,011.127 | -174,296.425 | -75,892.887 | -169,092.22 |
| Income Before Tax
| 237,848.825 | 431,445.937 | 377,509.627 | 195,503.438 | 176,640.361 | 109,673.318 | 121,308.935 | 111,358.495 | -56,815.848 | 65,779.041 | -31,506.009 |
| Income Before Tax Ratio
| 0.089 | 0.137 | 0.135 | 0.091 | 0.07 | 0.046 | 0.058 | 0.058 | -0.035 | 0.042 | -0.023 |
| Income Tax Expense
| 59,190.483 | 95,307.588 | 83,184.067 | 32,978.788 | 45,634.69 | 27,440.596 | 29,028.817 | 30,295.065 | -14,218.506 | 16,817.995 | 7,649.496 |
| Net Income
| 178,658.342 | 336,138.349 | 294,325.56 | 162,524.651 | 131,005.671 | 82,232.722 | 92,280.117 | 81,063.431 | -42,597.342 | 48,961.046 | -23,856.513 |
| Net Income Ratio
| 0.067 | 0.107 | 0.105 | 0.076 | 0.052 | 0.034 | 0.044 | 0.042 | -0.026 | 0.032 | -0.017 |
| EPS
| 56.64 | 106.57 | 107.12 | 51.53 | 41.54 | 26.07 | 29.26 | 35.77 | -19.14 | 22 | -10.72 |
| EPS Diluted
| 56.64 | 106.57 | 107.12 | 51.53 | 41.54 | 26.07 | 29.26 | 35.77 | -19.14 | 22 | -10.72 |
| EBITDA
| 366,091.834 | 468,221.489 | 416,311.028 | 325,943.492 | 278,004.976 | 295,858.444 | 260,176.414 | 245,263.769 | 206,450.11 | 223,464.328 | 215,743.022 |
| EBITDA Ratio
| 0.138 | 0.149 | 0.149 | 0.151 | 0.111 | 0.124 | 0.124 | 0.127 | 0.127 | 0.144 | 0.155 |